Papillomavirus and cervical cancer: epidemiological study in a population of women in eastern Algeria
Abstract
Cervical cancer, predominantly caused by the human papillomavirus (HPV), is a significant public health issue in Algeria. While HPV is the primary pathogenic agent and sexually transmitted, other sexual and non-sexual factors also contribute as co-factors in the progression of HPV infection to cervical cancer. This study aims to identify the main risk factors associated with the development of cervical cancer in Algeria. The study included 54 women with cervical-vaginal smear abnormalities due to HPV infection, with an average age of 42.29 years (range: 25 to 65 years) and 7.40% being menopausal. Women married at an average age of 22.52 years, with 25.92% marrying before age 25 and 37.04% between 20 and 25 years. Parity ranged from 1 to 10 children, with an average of 4.96 births per woman. Among the women studied, 48.14% had an erosive cervix, 37.03% experienced cervix bleeding on contact, 11.11% had polypoid lesions, 7.4% were diabetic, and 7.4% had a history of recurrent genital infection. Cervical cancer is preventable through vigilant screening and early diagnosis. With an estimated incidence of 15.6 per 105,000 women annually, it ranks as the second most common cancer in Algerian women, leading to significant morbidity and mortality. Emphasizing the importance of timely detection, this study highlights the need for proactive measures to combat cervical cancer, reducing its human and financial burdens.
Downloads
References
2. World Health Organization. Cancer control as part of an integrated approach [in French]. Geneva, WHO; 2017 (A70/32).
3. Haie-Meder C, Morice P, Castiglione M, ESMO Guidelines Working Group. Cervical cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008; 19(Suppl 2): ii17-18.
4. World Health Organization, Human papillomavirus (HPV) and cervical cancer [fact sheet], Available from: https://www.who.int/en/news-room/fact-sheets/detail/ human-papillomavirus-(hpv)-and-cervical-cancer, Accessed date: 17 October 2019
5. Verssimo J, de Medeiros Fernandes TAA. Human Papillomavirus: Biology and Pathogenesis. InTech, 2012. doi: 10.5772/27154.
6. Kouskous F. Cancer of the cervix: anatomopathological study (about 86 cases). [in French] Doctoral thesis. Medicine. Fez University of Sidi Mohammed Ben, 2012.
7. Laffargue F, Giancalone L. Cancer of the cervix: pathological rapid-anatomy screening, diagnosis, evolution, prognosis treatment [in French]. Rev Prat. 2015; 42(20): 2615.
8. Boublenza L, Hassaine H, Hoceini A, Zilabdi M, Masdoua N. Retrospective study of the evaluation of screening activities for precancerous lesions of the cervix in a region south of Algiers [in French]. Afr J Cancer. 2015; 7: 168-172.
9. Chaouki N, Bosch FX, Muñoz N, Meijer CJ, El Gueddari B, El Ghazi A, et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer. 2012; 75: 546-554
10. Bongain A, Galiba E, Rampal A, Gaid V, Durant J, Gillet JY. Cervical dysplasia in HIV-infected women [In French]. Reprod Hum Horm. 2015; 8(1-2): 73-79.
11. Lavoue V, Levêque J. Screening for cervical cancer in France: a new tool to do better or to do better with a new tool? [in French]. Gynecology Obstetrics & Fertility 2013.
12. Lei J, Ploner A, Elfström KM, Jiangrong Wang J, Roth AMD, Fang Fang D, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020; 383: 1340-1348.
13. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021; 9(2): e161-e169.
14. Bannour N, Boughizane S, Naifer R, Slama O, Trabelsi A, Bibi M, et al. Invasive cancer of the cervix in the Tunisian center. Epidemiological, clinical and therapeutic approaches. Retrospective study of 96 cases [In French]. Oncologie. 2004; 6: 481-488.
15. Nkegoum B, Belley Preso E, Mbakop A, Gwet Bell E. Precancerous lesions of the cervix in Cameroonian women [in French]. Cytological and epidemiological aspects of 946 cases. Gynecol Obstet Fertil. 2014; 29: 15-20.
16. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2015; 24 Suppl 3: S26-S34.
17. Hantz S, Alain S, Denis F. Prophylactic papillomavirus vaccines: issues and perspectives [In French]. Gynecol Obstet Fertil. 2013; 34: 647-655.
18. Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014; 134(9): 2264-2268.
19. Hinkula M, Pukkala E, Kyyrönen P, Laukkanen, Koskela P, Paavonen P, et al. A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland. Br J Cancer. 2004; 90: 1025-1029.
20. Ferrera A, Velema JP, Figueroa M, Bulnes R, Toro LA, Claros JM, et al. Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol. 2000; 29(5): 817-825.
21. Gros C, Matos S. New recommendations in the prevention of cervical cancer. [In French]. Press Med. 2017; 11: 8.
22. Chiang JW. Premalignant Lesions of the Endometrium. 2013: http://emedicine.medscape.com/article/269919-overview#showall
23. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002; 359(9312): 1085-1092.
24. El gnaoui N, Gazzaz B, Khyatti M, Benchakroune N, Bennidder A, Hassar M, et al. Rôle des papillomavirus humains (HPV) dans le cancer du col de l’utérus au Maroc et facteurs associés [in French]. J Biol Santé Casablanca, 2004.
25. Brenner DR, Speidel T, Csizmadi I, Biel RK, Cook LS, et al. Glycemic load and endometrial cancer risk in a case-control study of Canadian women. Cancer Epidemiol. 2015; 39(2): 170-173.
This work is licensed under a Creative Commons Attribution 4.0 International License.
